1. Home
  2. NTHI
  3. NTHI News

Latest NeOnc Technologies Holdings Inc. Common Stock (NTHI) News on June 1, 2025

NTHI

Argus Research

2 days ago

Daily – Vickers Top Insider Picks for 05/30/2025

NTHI

Argus Research

3 days ago

Daily – Vickers Top Insider Picks for 05/29/2025

NTHI

Argus Research

4 days ago

Daily – Vickers Top Insider Picks for 05/28/2025

NTHI

Argus Research

5 days ago

Daily – Vickers Top Insider Picks for 05/27/2025

NTHI

MT Newswires

a month ago

Top Premarket Decliners

NeOnc Technologies Global Patent Portfolio Covers Core Pipeline Across All Major Pharmaceutical Markets
NTHI

GlobeNewswire

2 months ago

NeOnc Technologies Global Patent Portfolio Covers Core Pipeline Across All Major Pharmaceutical Markets

NTHI

MT Newswires

2 months ago

NeOnc Technologies Expects Full Enrollment in Phase 2a Trialfor NEO100-01 by September

NeOnc Technologies Holdings, Inc. Expects Full Enrollment in Promising Phase 2a Trial of NEO100-01 for Malignant Gliomas in September
NTHI

GlobeNewswire

2 months ago

NeOnc Technologies Holdings, Inc. Expects Full Enrollment in Promising Phase 2a Trial of NEO100-01 for Malignant Gliomas in September

NTHI

MT Newswires

2 months ago

NeOnc Technologies Appoints Executive Chairman Amir Heshmatpour as President

NeOnc Technologies Holdings, Inc. Executive Chairman, Amir Heshmatpour, Assumes Expanded Leadership Role as Company’s New President
NTHI

GlobeNewswire

2 months ago

NeOnc Technologies Holdings, Inc. Executive Chairman, Amir Heshmatpour, Assumes Expanded Leadership Role as Company’s New President

NTHI

MT Newswires

2 months ago

Sector Update: Health Care Stocks Fall Premarket Wednesday

NTHI

MT Newswires

2 months ago

NeOnc Technologies Phase 1 Trial Enrollment for NEO212 Brain Cancer Drug Nears Full Enrollment

NeOnc Technologies Announces Near Completion of Phase I Enrollment for NEO212 Brain Cancer Therapy
NTHI

GlobeNewswire

2 months ago

NeOnc Technologies Announces Near Completion of Phase I Enrollment for NEO212 Brain Cancer Therapy

NTHI

MT Newswires

2 months ago

NeOnc Technologies Holdings' Perillyl Alcohol Receives FDA's Rare Pediatric Disease Designation

NeOnc Technologies Holdings, Inc. Receives Rare Pediatric Disease Designation for NEO100 in Treatment of Pediatric-Type Diffuse High-Grade Gliomas
NTHI

GlobeNewswire

2 months ago

NeOnc Technologies Holdings, Inc. Receives Rare Pediatric Disease Designation for NEO100 in Treatment of Pediatric-Type Diffuse High-Grade Gliomas

NeOnc Technologies Expands Global Clinical Trial Network with CBCC Global Research to Accelerate Study of Brain Cancer Treatments
NTHI

GlobeNewswire

2 months ago

NeOnc Technologies Expands Global Clinical Trial Network with CBCC Global Research to Accelerate Study of Brain Cancer Treatments

Share on Social Networks: